Form 4: Korro Bio Director Ali Behbahani Receives Stock Options

Director Ali Behbahani was granted 14,677 stock options in Korro Bio, Inc. as part of standard director compensation.

Summary

• Director Ali Behbahani received a grant of 14,677 stock options for Korro Bio, Inc. (KRRO) common stock.
• The options have an exercise price of $10.59 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $10.59 exercise price.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with corporate performance.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation packages for non-employee directors in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common governance practices to ensure board continuity.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Korro Bio, KRRO, Form 4, Insider Trading, Stock Options, Director Compensation